Edition:
India

Biofrontera AG (BFRA.OQ)

BFRA.OQ on NASDAQ Stock Exchange Capital Market

17.23USD
18 Jul 2019
Change (% chg)

-- (--)
Prev Close
$17.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
358
52-wk High
$18.22
52-wk Low
$11.05

Latest Key Developments (Source: Significant Developments)

Biofrontera AG H1 Sales Of About EUR 13.8-14.0 Mln
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: BIOFRONTERA REPORTS PRELIMINARY UNAUDITED SALES REVENUE FOR THE FIRST SIX MONTHS OF 2019.H1 SALES OF ABOUT EUR 13.8 TO 14.0 MILLION.H1 SALES OF AMELUZ IN U.S. WERE BETWEEN EUR 9.5 AND 9.7 MILLION, COMPARED TO EUR 6.4 MILLION (+50%) YEAR AGO.REVENUE IN GERMANY INCREASED BY ABOUT 82% TO EUR 2.1 TO 2.2 MILLION IN FIRST HALF OF 2019.  Full Article

Biofrontera Removes AGM Agenda Item Including Dr. Granzer's Removal From Supervisory Board
Friday, 5 Jul 2019 

July 5 (Reuters) - BIOFRONTERA AG ::DISMISSING AGM AGENDA ITEM 10 (INCLUDING THE REMOVAL OF DR. GRANZER FROM THE SUPERVISORY BOARD).IF UNDER ITEM 11 OF AGENDA DR. ING. BORER IS REMOVED FROM SUPERVISORY BOARD, TO PROPOSE PROF. DR. FRANCA RUHWEDEL TO SUCCEED DR. BORER.  Full Article

Biofrontera: Board Recommends Not To Accept Deutsche Balaton And Delphi Offer
Monday, 1 Jul 2019 

July 2 (Reuters) - Biofrontera AG ::SAID ON MONDAY IN A JOINT STATEMENT, EXECUTIVE BOARD AND MANAGEMENT BOARD OF BIOFRONTERA AG RECOMMEND NOT TO ACCEPT THE PARTIAL ACQUISITION OFFER OF DEUTSCHE BALATON BIOTECH AG AND DELPHI UNTERNEHMENSBERATUNG AKTIENGESELLSCHAFT.THE EMPLOYEES OF BIOFRONTERA AG ALSO REJECT THE PARTIAL ACQUISITION OFFER OF DEUTSCHE BALATON BIOTECH AG AND DELPHI UNTERNEHMENSBERATUNG AKTIENGESELLSCHAFT IN AN OWN STATEMENT.  Full Article

DB Biotech, Delphi Hike Offer For Biofrontera Shares
Monday, 1 Jul 2019 

July 1 (Reuters) - Deutsche Balaton's Deutsche Balaton Biotech AG::SAYS DEUTSCHE BALATON BIOTECH AG, DELPHI UNTERNEHMENSBERATUNG AG DECIDE TO RAISE OFFER PRICE FOR BIOFRONTERA AG B8FGN.DE SHARES.SAYS NOW OFFERING 8 EUR IN CASH FOR EACH BIOFRONTERA SHARE.SAYS NEW OFFER PRICE FOR UP TO 500,000 SHARES IN BIOFRONTERA IS 11% ABOVE RIVAL OFFER BY MARUHO DEUTSCHLAND GMBH.  Full Article

Biofrontera Q1 Prelim Revenue At About EUR 6.8 Million
Monday, 15 Apr 2019 

April 15 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: BIOFRONTERA REPORTS PRELIMINARY UNAUDITED SALES REVENUE FOR THE FIRST THREE MONTHS OF 2019.PRELIMINARY UNAUDITED REVENUE OF COMPANY FOR PERIOD JANUARY TO MARCH 2019 WAS AROUND EUR 6.8 MILLION.Q1 PRELIMINARY UNAUDITED PRODUCT SALES IN U.S. ARE EXPECTED TO BE ABOUT EUR 5.2 MILLION, VERSUS EUR 3.4 MILLION YEAR AGO.  Full Article

Biofrontera: Information On Announced Voluntary Public Tender Offer By Maruho Deutschland
Tuesday, 2 Apr 2019 

April 2 (Reuters) - BIOFRONTERA AG ::BIOFRONTERA PROVIDES INFORMATION ON ANNOUNCED VOLUNTARY PUBLIC TENDER OFFER BY MARUHO DEUTSCHLAND GMBH.MANAGEMENT BOARD OF BIOFRONTERA AG VALUES MARUHO AS A STRATEGICALLY ORIENTED LONG-TERM PARTNER.MARUHO TO OFFER TO SHAREHOLDERS OF BIOFRONTERA AG TO ACQUIRE A TOTAL OF UP TO 4,322,530 NO-PAR VALUE REGISTERED SHARES.ACQUISITION AGAINST PAYMENT OF EUR 6.60 PER SHARE IN CASH.BIOFRONTERA - MANAGEMENT BOARD REGARDS MARUHO'S INTEREST IN INCREASE IN ITS SHAREHOLDING AS AFFIRMATION OF PATH IT HAS TAKEN TO MAKE BIOFRONTERA A LEADING SPECIALIST IN DERMATOLOGY.  Full Article

Biofrontera Receives FDA Approval For Upscaling Of Batch Size For Ameluz(R) Production
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - BIOFRONTERA AG ::RECEIVES FDA APPROVAL FOR UPSCALING OF BATCH SIZE FOR AMELUZ(R) PRODUCTION.SAYS US FDA AND EUROPEAN MEDICINES AGENCY APPROVED UPSCALING OF BATCH SIZE FOR PRODUCTION OF AMELUZ^(R) TO 35 KG FROM PREVIOUSLY 7 KG.FDA-APPROVAL IS EFFECTIVE JANUARY 3, 2019.  Full Article

Biofrontera Publishes Review Of Capital Increase In February 2018
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Biofrontera AG ::PUBLISHES THE RESULT OF THE INDEPENDENT REVIEW OF THE CAPITAL INCREASE IN FEBRUARY 2018.SAYS REVIEW CONCLUDES ALLEGATIONS OF ILLEGITIMACY REGARDING BIOFRONTERA'S FEBRUARY 2018 CAPITAL INCREASE ARE UNFOUNDED.  Full Article

Biofrontera: Swissmedic Approves Ameluz In Combination With Daylight Photodynamic Therapy In Switzerland
Monday, 1 Oct 2018 

Oct 1 (Reuters) - BIOFRONTERA AG ::SWISSMEDIC APPROVES AMELUZ(R) IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY IN SWITZERLAND.BIOFRONTERA AND LOUIS WIDMER SEE SALES EFFECT FOR SUMMER MONTHS OF 2019 COMPARABLE TO ONE IN GERMAN MARKET THIS YEAR.  Full Article

Deutsche Balaton Biotech: Offer For Biofrontera Shares To Be Carried Out On Schedule
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Deutsche Balaton Biotech AG::Voluntary Purchase Offer For 6.25 Million Biofrontera <<>> SHARES WILL BE CARRIED OUT ON SCHEDULE.DEUTSCHE BALATON AG BIOTECH AG - AS ALREADY ANNOUNCED, VOLUNTARY OFFER ENDS ON 6TH AUGUST 2018.DEUTSCHE BALATON BIOTECH AG - AS ALREADY ANNOUNCED, VOLUNTARY OFFER ENDS ON 6TH AUGUST 2018.  Full Article